Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1095-1103

  Brusic, Ana ^a,b   Hainz, Ursula ^a   Wadleigh, Martha ^a,c   Neuberg, Donna ^a   Su, Mei ^a   Canning, Christine M ^a   DeAngelo, Daniel J ^a,c   Stone, Richard M ^a,c   Lee, Jeng Shin ^d   Mulligan, Richard C ^d   Ritz, Jerome ^a,c   Dranoff, Glenn ^a,c   Sasada, Tetsuro ^a   Wu, Catherine J ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MONASH UNIVERSITY   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chronic myeloid leukemia; Cross presentation; GM CSF; Immune monitoring; K562; Whole cell vaccine

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERFERON; TUMOR CELL VACCINE; VIRUS PROTEIN;

ADULT; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER REGRESSION; CASE REPORT; CD8+ T LYMPHOCYTE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DNA MODIFICATION; DONOR LYMPHOCYTE INFUSION; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET B RADIATION;

EID: 84883549115     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20954     Document Type: Article

References (54)

1. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18:569-84; PMID:15271393; http:// dx.doi.org/10.1016/j.hoc.2004.03.011.
2. Wu CJ. Immunological targeting of the cancer stem cell. In: The Stem Cell Research Community, Ed. Stembook: Stembook 2008.
3. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103:1037-42; PMID:14504104; http://dx.doi.org/10.1182/blood- 2003-03-0954.
4. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365:657-62; PMID:15721470.
5. Jain N, Kantarjian HM, Garcia-Manero G, Borthakur G, Ebarb T, Cortes JE. Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: A phase II trial. Journal of Clinical Oncology, 2008 ASCo. Annual meeting Proceedings (Post-Meeting Edition) 2008; 26:7056.
6. el-Shami K, Smith BD. Immunotherapy for myeloid leukemias: current status and future directions. Leukemia 2008 22:1658-64; PMID:18563174; http://dx.doi.org/10.1038/leu.2008.148.
7. Mittal S, Marshall NA, Barker RN, Vickers MA. Immunomodulation against leukemias and lymphomas: a realistic future treatment. Crit Rev Oncol Hematol 2008; 65:101-8; PMID:17719232; http:// dx.doi.org/10.1016/j.critrevonc.2007.05.004.
8. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi. org/10.1038/nm1100.
9. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cellbased vaccines. Cancer Immunol Immunother 2008; 57:1569-77; PMID:18523771; http://dx.doi. org/10.1007/s00262-008-0536-z.
10. Ward S, Copier J, Dalgleish A. Technical challenges facing therapeutic cancer vaccines. Curr Opin Drug Discov Devel 2008; 11:168-77; PMID:18283604.
11. Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2009; 113:18-27; PMID:18809757; http://dx.doi.org/10.1182/blood-2008-06-165654.
12. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviralmediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21:3343-50; PMID:12947071; http://dx.doi. org/10.1200/JCO.2003.07.005.
13. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010; 16:338-47; PMID:20048335; http://dx.doi.org/10.1158/1078-0432.CCR-09-2046.
14. Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, et al. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res 2005; 125:173-81; PMID:15854671; http://dx.doi. org/10.1016/j.jss.2004.11.036.
15. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; http://dx.doi.org/10.1038/32183.
16. Blachère NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 2005; 3:185; PMID:15839733; http://dx.doi.org/10.1371/journal.pbio.0030185.
17. Benencia F, Courrèges MC, Coukos G. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008; 6:21; PMID:18445282; http://dx.doi.org/10.1186/1479-5876-6-21.
18. Orange DE, Jegathesan M, Blachère NE, Frank MO, Scher HI, Albert ML, et al. Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy. Prostate Cancer Prostatic Dis 2004; 7:63-72; PMID:14999241; http://dx.doi.org/10.1038/ sj.pcan.4500694.
19. Brusa D, Garetto S, Chiorino G, Scatolini M, Migliore E, Camussi G, et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 2008; 26:6422-32; PMID:18848858; http://dx.doi.org/10.1016/j.vaccine. 2008.08.063.
20. Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Osterborg A, et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18:1810-5; PMID:15385926; http:// dx.doi.org/10.1038/sj.leu.2403517.
21. Kotera Y, Shimizu K, Mulé JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001; 61:8105-9; PMID:11719436.
22. Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Röbe J, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting crosspriming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 2002; 62:2347-52; PMID:11956095.
23. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol 2000; 61:438-52; PMID:10773346; http://dx.doi. org/10.1016/S0198-8859(00)00105-1.
24. Mirmonsef P, Tan G, Zhou G, Morino T, Noonan K, Borrello I, et al. Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood 2008; 111:2112-21; PMID:18063750; http://dx.doi.org/10.1182/blood- 2007-06-096586.
25. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled. Bone Marrow Transplant 2008; 42:569-79; PMID:18711351; http://dx.doi.org/10.1038/ bmt.2008.259.
26. Nijmeijer BA, van Schie MLJ, Verzaal P, Willemze R, Falkenburg JHF. Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia. Exp Hematol 2005; 33:1172-81; PMID:16219539; http://dx.doi. org/10.1016/j.exphem.2005.06.034.
27. Zhang W, Choi J, Zeng W, Rogers SA, Alyea EP, Rheinwald JG, et al. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res 2010; 16:2729-39; PMID:20460482; http://dx.doi. org/10.1158/1078-0432.CCR-10-0415.
28. Norde WJ, Overes IM, Maas F, Fredrix H, Vos JCM, Kester MGD, et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood 2009; 113:2312-23; PMID:19074734; http://dx.doi. org/10.1182/blood-2008-04-153825.
29. Johnson RS, Walker AI, Ward SJ. Cancer vaccines: will we ever learn. Expert Rev Anticancer Ther 2009; 9:67-74; PMID:19105708; http://dx.doi. org/10.1586/14737140.9.1.67.
30. Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, Mackiewicz A. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther 2010; 17:465-75; PMID:20168352; http://dx.doi.org/10.1038/ cgt.2010.2.
31. Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, et al. Phase I trial of TGFβ2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 2011; 17:183-92; PMID:21208907; http://dx.doi.org/10.1158/1078-0432.CCR-10-2195.
32. Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009; 16:620-4; PMID:19287371; http://dx.doi.org/10.1038/ cgt.2009.15.
33. Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother 2010; 59:379-88; PMID:19711075; http://dx.doi. org/10.1007/s00262-009-0756-x.
34. Qi CJ, Ning YL, Han YS, Min HY, Ye H, Zhu YL, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother 2012; 1-10; PMID:22086162.
35. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-a2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009; 15:4986-92; PMID:19622576; http://dx.doi.org/10.1158/1078-0432.CCR-08-3240.
36. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14:3098-104; PMID:18483377; http://dx.doi.org/10.1158/1078-0432.CCR-07-4875.
37. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363:594-9; PMID:14987883; http:// dx.doi.org/10.1016/S0140-6736(04)15590-6.
38. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, et al. A chaperone proteinenriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol Cancer Ther 2008; 7:721-9; PMID:18347157; http://dx.doi.org/10.1158/1535-7163.MCT-07-2067.
39. Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft-versus- leukemia reactions. Curr Opin Hematol 2002; 9:503-8; PMID:12394172; http://dx.doi. org/10.1097/00062752-200211000-00006.
40. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89:1405-12; PMID:9028964.
41. Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk Res 1979; 3:363-70; PMID:95026; http://dx.doi. org/10.1016/0145-2126(79)90033-X.
42. Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005; 174:8210-8; PMID:15944330.
43. Smith B, Kasamon Y, Miller C, Chia C, Murphy K, Kowalski J, et al. K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) oatients with residual disease on imatinib mesylate (IM). Blood (ASH Annual Meeting Abstracts) 2005; 106.
44. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102:1435-42; PMID:12714512; http:// dx.doi.org/10.1182/blood-2002-09-2828.
45. Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 2009; 106:15825-30; PMID:19717467; http://dx.doi.org/10.1073/pnas.0908358106.
46. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 2011; 3:80; PMID:21525398; http://dx.doi.org/10.1126/scitranslmed.3002207.
47. Ruffini PA, Di Nicola M, Carlo-Stella C, Siena S, Gianni AM. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma. Curr Gene Ther 2005; 5:511-21; PMID:16250891; http://dx.doi.org/10.2174/156652305774329221.
48. Nagarajan S, Selvaraj P. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Vaccine 2006; 24:2264-74; PMID:16376465; http://dx.doi.org/10.1016/j.vaccine. 2005.11.045.
49. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 2007; 15:981-8; PMID:17375070; http://dx.doi.org/10.1038/ mt.sj.6300134.
50. Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009; 114:1736-45; PMID:19556425; http://dx.doi. org/10.1182/blood-2009-02-205278.
51. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advancedstage non-small-cell lung cancer. Cancer Gene Ther 2006; 13:555-62; PMID:16410826; http://dx.doi. org/10.1038/sj.cgt.7700922.
52. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78:5535-45; PMID:15140950; http://dx.doi.org/10.1128/ JVI.78.11.5535-45.2004.
53. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18:226-32; PMID:17116643; http://dx.doi.org/10.1093/annonc/ mdl158.
54. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest 2007; 117:1902-13; PMID:17557120; http://dx.doi. org/10.1172/JCI30966.